Semnur Pharmaceuticals, Inc. (SMNR)
OTC Markets OTCPK
Price as at 1 Oct 2026, 01:36 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Semnur Pharmaceuticals, Inc. trades at $0.57. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its SMNR data?
Fundamentals for SMNR come from company filings and exchange data, as listed on OTC Markets OTCPK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 01:36 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for SMNR, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.